Blue Trust Inc. Purchases 641 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

Blue Trust Inc. increased its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 174.7% in the 3rd quarter, HoldingsChannel reports. The firm owned 1,008 shares of the biopharmaceutical company’s stock after acquiring an additional 641 shares during the quarter. Blue Trust Inc.’s holdings in Xenon Pharmaceuticals were worth $39,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the company. PNC Financial Services Group Inc. bought a new position in shares of Xenon Pharmaceuticals in the fourth quarter worth about $91,000. nVerses Capital LLC bought a new position in shares of Xenon Pharmaceuticals in the third quarter worth about $102,000. Quarry LP lifted its holdings in shares of Xenon Pharmaceuticals by 207.7% in the second quarter. Quarry LP now owns 4,000 shares of the biopharmaceutical company’s stock worth $156,000 after acquiring an additional 2,700 shares during the last quarter. EntryPoint Capital LLC bought a new position in shares of Xenon Pharmaceuticals in the first quarter worth about $195,000. Finally, ProShare Advisors LLC lifted its holdings in shares of Xenon Pharmaceuticals by 12.0% in the first quarter. ProShare Advisors LLC now owns 5,286 shares of the biopharmaceutical company’s stock worth $228,000 after acquiring an additional 565 shares during the last quarter. Institutional investors own 95.45% of the company’s stock.

Xenon Pharmaceuticals Stock Up 1.4 %

Shares of XENE stock opened at $41.69 on Friday. The company has a market cap of $3.16 billion, a price-to-earnings ratio of -15.22 and a beta of 1.25. Xenon Pharmaceuticals Inc. has a 52 week low of $27.99 and a 52 week high of $50.99. The firm has a 50 day moving average of $40.61 and a 200-day moving average of $40.17.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.05). During the same period in the prior year, the business earned ($0.72) EPS. Analysts anticipate that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on XENE shares. Royal Bank of Canada reiterated an “outperform” rating and issued a $55.00 price objective on shares of Xenon Pharmaceuticals in a report on Tuesday, September 3rd. HC Wainwright started coverage on shares of Xenon Pharmaceuticals in a report on Tuesday, October 1st. They issued a “buy” rating and a $53.00 price objective for the company. Wedbush dropped their price objective on shares of Xenon Pharmaceuticals from $50.00 to $49.00 and set an “outperform” rating for the company in a report on Friday, August 9th. Raymond James reiterated an “outperform” rating and issued a $50.00 price objective on shares of Xenon Pharmaceuticals in a report on Thursday, October 10th. Finally, William Blair raised shares of Xenon Pharmaceuticals to a “strong-buy” rating in a research report on Friday, August 30th. Eleven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Xenon Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $57.45.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.